http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++AltaGas+Ltd.ADR+++++++++++++++++++++++Filed+by%3A+BANK+OF+NEW+YORK++ADR+DIVISION/26582900.html si-local-file:///var/storage/secattach/20260601/26582900.html http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++AltaGas+Ltd.ADR+++++++++++++++++++++++Filed+by%3A+BANK+OF+NEW+YORK++ADR+DIVISION/26582900.html Mon, 01 Jun 2026 15:01:00 -0400 ALA ATGAF O.06052750 http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++AltaGas+Ltd.ADR+++++++++++++++++++++++Filed+by%3A+BANK+OF+NEW+YORK++ADR+DIVISION/26582900.html si-local-file:///var/storage/secattach/20260601/26582900.html http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++AltaGas+Ltd.ADR+++++++++++++++++++++++Filed+by%3A+BANK+OF+NEW+YORK++ADR+DIVISION/26582900.html Mon, 01 Jun 2026 15:01:00 -0400 ALA ATGAF O.06052750 http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++AltaGas+Ltd.ADR+++++++++++++++++++++++Filed+by%3A+BANK+OF+NEW+YORK++ADR+DIVISION/26582900.html si-local-file:///var/storage/secattach/20260601/26582900.html http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++AltaGas+Ltd.ADR+++++++++++++++++++++++Filed+by%3A+BANK+OF+NEW+YORK++ADR+DIVISION/26582900.html Mon, 01 Jun 2026 15:01:00 -0400 ALA ATGAF O.06052750 http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html <p align="justify">CALGARY, Alberta, May 20, 2026 (GLOBE NEWSWIRE) -- Keyera Corp. (TSX: KEY) (“Keyera”), AltaGas Ltd. (TSX: ALA) (“AltaGas”) and CN (TSX: CNR) (NYSE: CNI) today announced plans to advance the Alberta Corridor Export (“ACE”) Rail Terminal Project (the “Project”), a strategic Canadian energy infrastructure investment designed to strengthen Canada’s energy supply chain, further increasing Canadian competitiveness on the global markets. The partnership combines Keyera’s ACE Rail Terminal with CN’s rail network and AltaGas’ West Coast export platform.</p> <p align="justify">ACE will be owned and constructed by Keyera on Keyera-owned lands within Alberta’s Industrial Heartland and will be supported http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html Wed, 20 May 2026 07:00:00 -0400 ALA CNI CNR KEY O.00673992 O.00791121 O.06052750 http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html <p align="justify">CALGARY, Alberta, May 20, 2026 (GLOBE NEWSWIRE) -- Keyera Corp. (TSX: KEY) (“Keyera”), AltaGas Ltd. (TSX: ALA) (“AltaGas”) and CN (TSX: CNR) (NYSE: CNI) today announced plans to advance the Alberta Corridor Export (“ACE”) Rail Terminal Project (the “Project”), a strategic Canadian energy infrastructure investment designed to strengthen Canada’s energy supply chain, further increasing Canadian competitiveness on the global markets. The partnership combines Keyera’s ACE Rail Terminal with CN’s rail network and AltaGas’ West Coast export platform.</p> <p align="justify">ACE will be owned and constructed by Keyera on Keyera-owned lands within Alberta’s Industrial Heartland and will be supported http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html Wed, 20 May 2026 07:00:00 -0400 ALA CNI CNR KEY O.00673992 O.00791121 O.06052750 http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html <p align="justify">CALGARY, Alberta, May 20, 2026 (GLOBE NEWSWIRE) -- Keyera Corp. (TSX: KEY) (“Keyera”), AltaGas Ltd. (TSX: ALA) (“AltaGas”) and CN (TSX: CNR) (NYSE: CNI) today announced plans to advance the Alberta Corridor Export (“ACE”) Rail Terminal Project (the “Project”), a strategic Canadian energy infrastructure investment designed to strengthen Canada’s energy supply chain, further increasing Canadian competitiveness on the global markets. The partnership combines Keyera’s ACE Rail Terminal with CN’s rail network and AltaGas’ West Coast export platform.</p> <p align="justify">ACE will be owned and constructed by Keyera on Keyera-owned lands within Alberta’s Industrial Heartland and will be supported http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html Wed, 20 May 2026 07:00:00 -0400 ALA CNI CNR KEY O.00673992 O.00791121 O.06052750 http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html <p align="justify">CALGARY, Alberta, May 20, 2026 (GLOBE NEWSWIRE) -- Keyera Corp. (TSX: KEY) (“Keyera”), AltaGas Ltd. (TSX: ALA) (“AltaGas”) and CN (TSX: CNR) (NYSE: CNI) today announced plans to advance the Alberta Corridor Export (“ACE”) Rail Terminal Project (the “Project”), a strategic Canadian energy infrastructure investment designed to strengthen Canada’s energy supply chain, further increasing Canadian competitiveness on the global markets. The partnership combines Keyera’s ACE Rail Terminal with CN’s rail network and AltaGas’ West Coast export platform.</p> <p align="justify">ACE will be owned and constructed by Keyera on Keyera-owned lands within Alberta’s Industrial Heartland and will be supported http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html Wed, 20 May 2026 07:00:00 -0400 ALA CNI CNR KEY O.00673992 O.00791121 O.06052750 http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html <p align="justify">CALGARY, Alberta, May 20, 2026 (GLOBE NEWSWIRE) -- Keyera Corp. (TSX: KEY) (“Keyera”), AltaGas Ltd. (TSX: ALA) (“AltaGas”) and CN (TSX: CNR) (NYSE: CNI) today announced plans to advance the Alberta Corridor Export (“ACE”) Rail Terminal Project (the “Project”), a strategic Canadian energy infrastructure investment designed to strengthen Canada’s energy supply chain, further increasing Canadian competitiveness on the global markets. The partnership combines Keyera’s ACE Rail Terminal with CN’s rail network and AltaGas’ West Coast export platform.</p> <p align="justify">ACE will be owned and constructed by Keyera on Keyera-owned lands within Alberta’s Industrial Heartland and will be supported http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html Wed, 20 May 2026 07:00:00 -0400 ALA CNI CNR KEY O.00673992 O.00791121 O.06052750 http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html <p align="justify">CALGARY, Alberta, May 20, 2026 (GLOBE NEWSWIRE) -- Keyera Corp. (TSX: KEY) (“Keyera”), AltaGas Ltd. (TSX: ALA) (“AltaGas”) and CN (TSX: CNR) (NYSE: CNI) today announced plans to advance the Alberta Corridor Export (“ACE”) Rail Terminal Project (the “Project”), a strategic Canadian energy infrastructure investment designed to strengthen Canada’s energy supply chain, further increasing Canadian competitiveness on the global markets. The partnership combines Keyera’s ACE Rail Terminal with CN’s rail network and AltaGas’ West Coast export platform.</p> <p align="justify">ACE will be owned and constructed by Keyera on Keyera-owned lands within Alberta’s Industrial Heartland and will be supported http://www.streetinsider.com/Press+Releases/Keyera%2C+AltaGas+and+CN+Partner+to+Build+Strategic+Canadian+Infrastructure/26524637.html Wed, 20 May 2026 07:00:00 -0400 ALA CNI CNR KEY O.00673992 O.00791121 O.06052750